Vancouver, Canada — September 1, 2026
Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its investigational non-hallucinogenic psychedelic-derived neuroplastogen being evaluated as a potential treatment for Alcohol Use Disorder (AUD). Six patients have been enrolled to date, with three participants at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. The progression into Phase IIa follows completion of the initial safety evaluation in healthy volunteers and represents the first multiple-dose treatment phase involving patients with AUD.
CMND-100 Moves Into Multiple-Dose Patient Evaluation
The Phase I/IIa study is a double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of CMND-100 in individuals with moderate-to-severe AUD. The broader study consists of four parts evaluating single and multiple doses, tolerability, safety and pharmacokinetics in both healthy volunteers and participants with AUD. The Phase IIa portion will provide an early assessment of whether CMND-100 may demonstrate therapeutic activity in people living with AUD, a chronic disorder associated with persistent difficulty controlling alcohol consumption despite negative health, social and occupational consequences.
DSMB Review Supports Continued Clinical Development
Clearmind previously reported that an independent Data and Safety Monitoring Board (DSMB) reviewed clinical data from Part A and recommended progression into subsequent stages of the study. The favorable safety assessment supported continued evaluation of CMND-100, including multiple dosing in healthy volunteers and patient evaluation in the AUD population. The company reported that six patients have now been enrolled in Part C, representing approximately one-third of the planned enrollment for that portion of the trial.
Advertisement
Clearmind Develops Non-Hallucinogenic Psychedelic-Derived Medicines
CMND-100 is Clearmind’s lead investigational candidate within its pipeline of non-hallucinogenic, psychedelic-derived neuroplastogens. The company is developing these compounds for potential applications across addiction, neuropsychiatric and metabolic disorders. Clearmind’s intellectual property portfolio currently includes 19 patent families and 32 granted patents. The company’s continued development of CMND-100 is focused on determining whether its psychedelic-derived mechanism can provide a scalable therapeutic approach for AUD without the hallucinogenic effects associated with traditional psychedelic compounds.
Source:Clearmind Medicine, press relese
